Skip to NavigationSkip to content

top 10

Top Ten most popular articles on Pharmafile.com this week!

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia Pharmaceuticals in relation to Nuplazid, a psychosis drug for those with Parkinson’s disease.

Personal genomics company 23andMe, this week announced they would offer reports on customer’s likelihood they would develop type 2 diabetes. Meanwhile researchers published results showing a new class of drugs offered similar efficacy to statins.

Top Ten most popular articles on Pharmafile.com this week!

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ had been cured of HIV after receiving a bone marrow transplant from a donor with natural resistance to the immunodeficiency virus. Meanwhile Gilead offered positive results with HIV drug Biktarvy.

The news comes as sources told Reuters OxyContin drugmaker Purdue Pharma was exploring bankruptcy as a get out for the lawsuits they face over their role in manufacturing the opioid crisis.

Top Ten most popular articles on Pharmafile.com this week!

As the CRISPR twins’ story unfolds, scientists revealed that the Chinese babies were likely altered in a way that improves memory and cognition. Having opened a Pandora’s Box of ethical issues already, the prospect of performance enhancing genetic modification should force us to take action now!

Meanwhile are top story looked at a British scientist who developed a medical device able to inject drugs directly into the brain. The tech may open up new ways of treating an array of neurological conditions.

Top Ten most popular articles on Pharmafile.com this week!

News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, took the top spot this week. The therapy, based on party drug ketamine, may act as a significant breakthrough in the neglected area of mental health.

Other news saw England’s chief medical officer Dame Sally Davies, who is leaving her current role to become Master of trinity College Cambridge, suggest that as many as one third of antibiotics may be prescribed inappropriately.

Top Ten most popular articles on Pharmafile.com this week!

The strike in Ireland featured twice in this week’s top 10 after Pfizer employees in County Cork lost a dispute over pensions. Two of our features also appeared in the top stories of the week. While ‘Counterfeit drugs – countering the lies’, picks apart ‘common sense’ claims on counterfeit drugs in asking to what extent the problem of falsified medicines is a problem at all; ‘Repurposed drugs’ looks at the Supreme Court ruling on the Lyrica patent and asks what it means.

Top Ten most popular articles on Pharmafile.com this week!

Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a disreputable doctor a lap dance in an effort to persuade him to prescribe the potent opioid fentanyl to his patients. Meanwhile Vertex terminated COO Ian Smith over ‘personal behaviour’ while an Israeli biotech made the dubious claim that it had created a complete cure for cancer.

Top Ten most popular articles on Pharmafile.com this week!

Job switches were the theme of this week as AstraZeneca lost three, high levels executives to biotechs amid a restructuring of the organisation. Meanwhile Roche’s Cindy Perettie became Foundation Medicine’s CEO while the former CEO of Novartis Corporation joined the board of the Florida-based immunotherapy firm, ImmunSYS.

Top Ten most popular articles on Pharmafile.com this week!

With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US firm Bristol-Myers Squibb revealed that it would acquire Celgene in a deal worth $74 million. The news came after analysts suggested that $400 billion worth of M&A deals were expected for 2019.

Top Ten most popular articles on Pharmafile.com of 2018!

Image Credit: patricia m https://www.flickr.com/photos/taffeta/38707779504/

Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical industry continued to innovate. The top story of the year covered the fact that Amgen’s biosimilar prove non-inferior to Johnson & Johnson’s Remicade in rheumatoid arthritis. Meanwhile the British parliament’s choice to remain within the EMA regulatory network took second place, followed closely behind by the launch of another high profile biosimilar.

Top Ten most popular articles on Pharmafile.com this week!

Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration worth billions. Meanwhile Japanese company Taisho revealed they were set to buy Bristol-Myers Squibb’s consumer healthcare business in a deal worth $1.6 billion. To top it off Swiss pharma giant Novartis signed a deal with Canadian cannabis company which propelled the latter’s stocks up by more than 11%.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches